
TNDM Stock Forecast & Price Target
TNDM Analyst Ratings
Bulls say
Tandem Diabetes Care is a financially sound company with a strong first quarter that is transitioning to the pharmacy channel for increased profits. However, there are some uncertainties and potential risks that could affect short-term estimates. The company's success in converting patients to the pharmacy channel and maintaining favorable economics will be crucial for their future growth and profitability. Its lower margins and potential execution risks may result in a discounted valuation compared to its peers.
Bears say
Tandem Diabetes Care is facing risks to its growth potential due to the slow conversion of its existing patient base to the new pharmacy channel, as well as potential headwinds from the competition as they introduce new products. While the company is projecting revenue growth in the mid-single digits for FY26, it remains to be seen if they can successfully transition to a pay-as-you-go model and secure access to the pharmacy channel. Additionally, the international market presents a significant opportunity for growth, with potential annual renewal revenue of $100M+, but the company's plan to convert 70-80% of its existing US patient base to the pharmacy channel within 2-3 years may be too aggressive. Therefore, the financial analyst has a negative outlook for Tandem Diabetes Care's stock.
This aggregate rating is based on analysts' research of Tandem Diabetes Care and is not a guaranteed prediction by Public.com or investment advice.
TNDM Analyst Forecast & Price Prediction
Start investing in TNDM
Order type
Buy in
Order amount
Est. shares
0 shares